Impact of Serum High Mobility Group Box 1 and Soluble Receptor for Advanced Glycation End-Products on Subclinical Atherosclerosis in Patients with Granulomatosis with Polyangiitis

• Alexandre W. S. de Souza ,

  * E-mail: alexandre.wagner@unifesp.br

  Affiliations Department of Rheumatology and Clinical Immunology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands, Rheumatology Division, Universidade Federal de São Paulo/Escola Paulista de Medicina (Unifesp/EPM), São Paulo-SP, Brazil

  ⨯
• Karina de Leeuw,

  Affiliation Department of Rheumatology and Clinical Immunology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands

  ⨯
• Mirjan M. van Timmeren,

  Affiliation Department of Pathology and Medical Biology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands

  ⨯
• Pieter C. Limburg,

  Affiliation Department of Laboratory Medicine, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands

  ⨯
• Coen A. Stegeman,

  Affiliation Department of Internal Medicine, Division of Nephrology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands

  ⨯
• Marc Bijl,

  Affiliation Martini Hospital, Groningen, The Netherlands

  ⨯
• Johanna Westra,

  Affiliation Department of Rheumatology and Clinical Immunology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands

  ⨯
• Cees G. M. Kallenberg

  Affiliation Department of Rheumatology and Clinical Immunology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands

  ⨯